Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (311-320 of 352) with videos related to

Pageof 36
Sort By:
Gastroenterology|August 20, 2013
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONICMarc Ferrante, Jean-Frederic Colombel, William J Sandborn, et al.
Journal of Crohn'S & Colitis|November 24, 2020
Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD RegistryManasi Agrawal, Erica J Brenner, Xian Zhang, et al.
The Lancet. Gastroenterology & Hepatology|December 5, 2024
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trialSéverine Vermeire, Stefan Schreiber, David T Rubin, et al.
The Lancet. Gastroenterology & Hepatology|July 9, 2023
Difficult-to-treat inflammatory bowel disease: results from an international consensus meetingTommaso Lorenzo Parigi, Ferdinando D'Amico, Maria T Abreu, et al.
Frontiers in Immunology|May 31, 2022
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel DiseaseAngelika Wagner, Erika Garner-Spitzer, Anna-Margarita Schötta, et al.
Lancet (London, England)|May 22, 2017
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trialSéverine Vermeire, William J Sandborn, Silvio Danese, et al.
Gastroenterology|July 8, 2018
Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative ColitisShannon E Telesco, Carrie Brodmerkel, Hongyan Zhang, et al.
Gastroenterology|December 28, 2020
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBDDan Turner, Amanda Ricciuto, Ayanna Lewis, et al.
Gastroenterology|December 27, 2017
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's DiseaseJulián Panés, Damián García-Olmo, Gert Van Assche, et al.
Inflammatory Bowel Diseases|March 26, 2011
Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational studyMats Sjöberg, Andrea Walch, Mina Meshkat, et al.
Pageof 36

Showing results (311-320 of 352) with videos related to

Sort By:
Pageof 36
Gastroenterology|August 20, 2013
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONICMarc Ferrante, Jean-Frederic Colombel, William J Sandborn, et al.
Journal of Crohn'S & Colitis|November 24, 2020
Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD RegistryManasi Agrawal, Erica J Brenner, Xian Zhang, et al.
The Lancet. Gastroenterology & Hepatology|December 5, 2024
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trialSéverine Vermeire, Stefan Schreiber, David T Rubin, et al.
The Lancet. Gastroenterology & Hepatology|July 9, 2023
Difficult-to-treat inflammatory bowel disease: results from an international consensus meetingTommaso Lorenzo Parigi, Ferdinando D'Amico, Maria T Abreu, et al.
Frontiers in Immunology|May 31, 2022
SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel DiseaseAngelika Wagner, Erika Garner-Spitzer, Anna-Margarita Schötta, et al.
Lancet (London, England)|May 22, 2017
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trialSéverine Vermeire, William J Sandborn, Silvio Danese, et al.
Gastroenterology|July 8, 2018
Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative ColitisShannon E Telesco, Carrie Brodmerkel, Hongyan Zhang, et al.
Gastroenterology|December 28, 2020
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBDDan Turner, Amanda Ricciuto, Ayanna Lewis, et al.
Gastroenterology|December 27, 2017
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's DiseaseJulián Panés, Damián García-Olmo, Gert Van Assche, et al.
Inflammatory Bowel Diseases|March 26, 2011
Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational studyMats Sjöberg, Andrea Walch, Mina Meshkat, et al.
Pageof 36